Navigation Links
Medizone International, Inc. Announces Strategic Consulting Relationship With TDV Global, Inc.

SAN FRANCISCO, Nov. 4 /PRNewswire-FirstCall/ Medizone International, Inc. (Pink Sheets: MZEI) announces the establishment of a strategic consulting relationship with TDV Global, Inc. ( TDV Global is a highly professional and experienced strategic management consulting firm. Approximately 70% of their business involves consulting for government agencies and projects, the remainder for private enterprise, mostly in the Health and Security Medical fields. TDV Global has assisted Medizone with the founding of its recently established non-profit affiliate, The Canadian Foundation for Global Health (CFGH). Mr. Brad Goble, the President of TDV Global, has been appointed an officer and member of the Board of Directors of the Canadian Foundation for Global Health. Additionally, the offices for the CFGH are being located at TDV Global in Ottawa. Working with Dr. Michael E. Shannon of Medizone International, TDV Global has also played a key role in producing the product development plan for Medizone's Hospital Sterilization Initiative.

Edwin Marshall, Chairman of the Board and CEO of Medizone commented, "Over the past ten years, Dr. Shannon has successfully worked on many different projects with Mr. Goble and his firm. Between the Hospital Sterilization Initiative and founding the CFGH, Medizone has been working with TDV Global since mid-September. I could not be more pleased with the results so far. Given their many current health related activities involving G-8 countries, TDV will assist Medizone in strategically aligning us with government and institutional interests in Canada, the US and Europe. We welcome TDV Global as a vital and strategic partner."

Medizone International, Inc., is a research and development stage company engaged in the development of patented and unpatented technologies and protocols for O3 based bio-oxidative treatment of diseases caused by lipid enveloped viruses, including Acquired Immune Deficiency Syndrome (AIDS), Hepatitis B & C, and Herpes, the decontamination of blood, blood products and veterinarian serum products, and the treatment of external pathogenic conditions. It is currently developing technology to decontaminate and sterilize hospital surgical suites, emergency rooms and intensive care units.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.

Web site:

Investor Relations 800-953-3350

SOURCE Medizone International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Chindex International, Inc. Announces Preliminary Second Quarter Results and Improved Revenue Outlook for Fiscal 2009
2. Chindex International, Inc. Announces Appearances at Additional November Conferences
3. PharmaSmart International, Inc. Redefines Blood Pressure Management through Technology and Pharmacy Focused Patient Services
4. Animal Health International, Inc. Announces Its First Quarter Fiscal Year 2009 Earnings Release Date and Conference Call Information
5. China Yingxia International, Inc. to Promote Benefits of Its Soy Milk Products Over Scandal-Stricken Cows Milk in China
6. Block Imaging International, Inc. Partners with Dicom Solutions, Inc. to Offer New Products
7. Natural Alternatives International, Inc. Announces Fiscal 2008 Results
8. MINRAD International, Inc. Announces Change in Distribution Agreement with RxElite Holdings, Inc.
9. WaterPure International, Inc. and Everest Water Ltd. Revise Payment Terms of Patent License to Produce Water From Air
10. MINRAD International, Inc. to Discuss 2008 Second Quarter Financial Results on Thursday, August 14, 2008
11. Chindex International, Inc. Announces CDC Contract Signing
Post Your Comments:
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... States, today announced that its iconic bottle has won top honors in Beverage World ... The Company also announced that it has been selected as a 2015 U.S.A. ...
(Date:12/1/2015)... Houston, TX (PRWEB) , ... December 01, 2015 , ... ... owner of Vitenas Cosmetic Surgery, has been named by MedEsthetics magazine as the Best ... best of the best among the many elite aesthetic physicians honored by the industry ...
(Date:12/1/2015)... ... 01, 2015 , ... Speech and physical therapies are traditionally ... technologies and under the right circumstances, these practices can be merged. This ... to his or her therapeutic sessions, as well as gives the physical and ...
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per ... decreases in utilization of hospital and nonhospital care, according to a recent study by ... for Louisiana, 16th Edition , found medical payments per claim with more than seven ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... identification tests to continue the expansion of the company’s growing product line of ... for Chinook (Oncorhynchus tshawytscha) and Sockeye (Oncorhynchus nerka) – allow InstantLabs to offer ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015  Athletic apparel ... founder have agreed to pay $1.35 million to ... advertised the company,s copper-infused compression clothing would relieve ... arthritis and other diseases. Tommie ... requires the company and its founder and chairman ...
(Date:12/1/2015)... 2015 Pharma Tech Outlook recently conducted a ... Data Management Solution Providers - 2015 .  After careful ... CEOs, CIOs, VCs, analysts, and the Pharma Tech Outlook ... top 10 clinical data management solution providers (check out ... and 36 respectively). --> ...
(Date:12/1/2015)... and PITTSBURGH , Dec. ... announced that it expects to be the first to ... funded by international donors, TLE400 (Tenofovir Disoproxyl Fumarate 300 ... for $99 per patient, per year. Mylan partnered with ... The significantly reduced price could generate savings of tens ...
Breaking Medicine Technology: